Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer. Duquesne I, de la Taille A. Eur Urol 2024 Mar 26:S0302-2838(24)02206-1. doi: 10.1016/j.eururo.2024.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Duquesne I, de la Taille A. Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer. Eur Urol 2024 Mar 26:S0302-2838(24)02206-1. doi: 10.1016/j.eururo.2024.
PMID: 38538425